Search clinical trials for: 165-302

Total 1174 results

BioMarin Pharmaceutical

Completed

A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302 (PRISM303)

Phenylketonuria

United States
BioMarin Pharmaceutical

Completed

Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU (Prism-2)

Phenylketonuria (PKU)

United States
Shenzhen Xbiome Biotech Co., Ltd.
Beijing Improve-Quality Tech.Co., Ltd.

Recruiting

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Acute-graft-versus-host Disease

China
Takeda

Completed

Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2

Breast Neoplasm | Ovarian Neoplasm | Pancreatic Neoplasm | Lung Neoplasm | Renal Neoplasm

United States
Threshold Pharmaceuticals

Completed

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | High-risk Myelodysplastic Syndrome | Advanced Myelofibrosis

United States
Memorial Sloan Kettering Cancer Center

Completed

Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast

Kidney Cancer | Renal Cancer

United States
Myeloid Therapeutics

Recruiting

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony)

Epithelial Tumors, Malignant

Australia
Sarcoma Alliance for Research through Collaboration
Threshold Pharmaceuticals

No longer available

SARC021C: A Continuation Study of TH-CR-406/SARC021

Soft Tissue Sarcoma
Threshold Pharmaceuticals

Unknown

A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Akros Pharma Inc.

Completed

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Dyslipidemia

United States
Threshold Pharmaceuticals

Completed

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Hypoxia | Tumors

United States
Hospices Civils de Lyon

Unknown

Metabolic Impact of Fat Digestion (LIPINFLOX)

Obesity

France
Laboratorios Sophia S.A de C.V.

Active, not recruiting

Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel (PRO-165)

Dry Eye Syndromes

Mexico
Qualigen Theraputics, Inc.
Translational Drug Development

Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Solid Tumor

United States
Threshold Pharmaceuticals

Terminated

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

Metastatic Melanoma

United States, Canada
FSD Pharma, Inc.
Lucid Psycheceuticals Inc. (sub of FSD Pharma, Inc.)

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy Volunteers

Healthy Participants

Canada
LaNova Medicines Zhejiang Co., Ltd.

Active, not recruiting

Study of LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

China
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Dyslipidemia

United States
Braintree Laboratories

Completed

Study 302: BLI4900 Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy

Colonoscopy

United States
Selecta Biosciences, Inc.
National Human Genome Research Institute (NHGRI)

Suspended

A Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 in Pediatric Subjects With MMA (reiMMAgine)

Methylmalonic Acidemia (MMA)

United States
LaNova Australia Pty Limited

Terminated

Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Northwestern University
Brain & Behavior Research Foundation; Neurocentria, Inc.

Completed

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States
Herbert Hurwitz, MD
GlaxoSmithKline; National Comprehensive Cancer Network; Threshold Pharmaceuticals

Completed

Dose Escalation Study of Pazopanib Plus TH-302 (PATH)

Solid Tumors

United States
Seoul National University Hospital
Threshold Pharmaceuticals

Completed

Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Yooyoung Pharmaceutical Co., Ltd.

Completed

Clinical Trial of YYD302 for Treatment of Osteoarthritis of the Knee

Osteoarthritis, Knee

Korea, Republic of
BioMarin Pharmaceutical

No longer available

Extension Study of Drisapersen in DMD Subjects

Duchenne Muscular Dystrophy

United States, Germany, United Kingdom, Japan, Netherlands, France, Spain, Korea, Republic of, Italy, Belgium, Taiwan, Argentina, Australia, Bulgaria, Czechia, Israel, Norway, Poland, Russian Federation, Turkey
Sanofi

Completed

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Hematopoietic Neoplasm

United States
Sanofi

Completed

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

Hematopoietic Neoplasm

Austria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Arcturus Therapeutics, Inc.

Recruiting

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

COVID-19 | Corona Virus Infection | SARS-CoV-2 Infection

United States, Singapore
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment

Renal Impairment

United States
Sanofi

Completed

Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Hepatic Impairment

United States
BioMarin Pharmaceutical

Recruiting

A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace) (PALace)

Phenylketonuria (PKU)

United States, Germany, Italy
Sanofi

Completed

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

Hematopoietic Neoplasm

United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
Merck KGaA, Darmstadt, Germany
Threshold Pharmaceuticals

Completed

A Phase 1 TH-302 Mass Balance Trial

Solid Tumor

Germany
Beam Therapeutics Inc.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Alpha 1-Antitrypsin Deficiency

United Kingdom
Threshold Pharmaceuticals

Terminated

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Pancreatic Cancer

United States
Threshold Pharmaceuticals

Unknown

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (TH-CR-410)

Gastrointestinal Stromal Tumors | Advanced Renal Cell Carcinoma | Pancreatic Neuroendocrine Tumors

United States
Pamela Munster

Withdrawn

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Advanced Solid Tumor | Brain Metastases | Documented Her2 Overexpression | Neurologically Stable
Threshold Pharmaceuticals
M.D. Anderson Cancer Center

Unknown

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Melanoma | Pancreatic Cancer | Prostate Cancer | Squamous Cell Carcinoma of the Head and Neck

United States
Beijing 302 Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells

Hepatocellular Carcinoma

China
NuCana plc

Completed

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Colorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal

United States, France, United Kingdom
Threshold Pharmaceuticals

Completed

Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States
Beijing 302 Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing...

Unknown

Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial

Hepatocellular Carcinoma

China
InQpharm Group

Completed

Benefit and Tolerability of IQP-AE-103 in Weight Loss

Obesity | Overweight

Germany
Therapure Biopharma Inc

Unknown

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Turning Point Therapeutics, Inc.

Completed

Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Advanced Solid Tumor

United States
University of Wisconsin, Madison

Completed

Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Threshold Pharmaceuticals

Completed

Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO)

Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma

United States, Germany
Memorial Sloan Kettering Cancer Center

Completed

PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer

Esophagogastric Cancer

United States

Search clinical trials for: 165-302

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations